Search NLS News

Ilya Pharma is planning to submit an Investigational New Drug Application (IND) for a Phase 1/2a safety and dose finding clinical study of ILP100-Oral, the company’s investigational immunotherapy being developed for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors. “Immune checkpoint inhibitors (ICI’s) have provided a welcome new front line range […]

Orion Corporation and CuraTeQ Biologics have expanded their biosimilar distribution agreement to the Baltic countries. The original marketing and distribution agreement signed in 2020 covered the Nordics, Austria, Hungary and Slovenia. Under the agreement, Orion will have the right to sell and market CuraTeQ’s biosimilars in the Nordics, the Baltics, Austria, Hungary and Slovenia. All […]

Rafael Natanek was raised and educated in Sweden. He spent 15 years working out of the UK, serving life science companies across Europe and the U.S. Today he is located in the Netherlands, investing in and supporting life science companies across Northern Europe to grow their businesses. “The largest difference is really between the US […]

Valo Therapeutics has announced the acquisition of intellectual property rights from the University of Helsinki for the technology which utilizes pre-existing immunity (PEI) against pathogens to enhance the therapeutic efficacy of ValoTx’s lead platform, PeptiCRAd. This approach takes advantage of existing acquired immunity (generated, for example, through vaccination against pathogens) by including pathogen specific peptides […]

Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). NI006 specifically targets misfolded transthyretin and is designed to directly address the pathology of ATTR-CM by enabling removal […]

Rupert Sandbrink joined Lundbeck on 1 January 2022 as Senior Vice President, Head of Clinical Development. Sandbrink will play a vital role in advancing Lundbeck’s clinical pipeline towards providing transformative medicines for people living with niche and rare brain diseases, the company states. “I am looking forward to Rupert joining our R&D team. He brings […]

The Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company. LEO Pharma has recently completed the first phase of its strategic transformation process – including the development of a new capital and governance structure. The next phase […]

Elekta will appoint Tobias Hägglöv as Chief Financial Officer effective February 1, 2022, taking over from Johan Adebäck. “I’m very pleased that Tobias will join Elekta. He brings strong expertise within finance and IT as well as broad experience from multinational companies. Elekta is fully focused on delivering on our ACCESS 2025 strategy and is […]

Immunicum has announced to transfer its patent rights for modified adenovirus (patent US 9,017,672 B2) to Elicera Therapeutics. The patent is currently out-licensed to Elicera and covers a modified adenovirus that improves gene delivery and tumor cell killing efficiency. “We are happy to enable Elicera to strengthen its patent position for its lead program while […]

Sound Bioventures, a new Scandinavia-based life sciences venture capital firm, has announced the first close of its first fund. The fund has a geographic footprint on both sides of the Atlantic and will invest in European and US-based private biotech companies supporting the clinical development of novel medicines for diseases of high unmet medical need. […]